ImmunoGen, Gilead To Evaluate Pivekimab With Magrolimab In R/R CD123-positive Acute Myeloid Leukemia

(RTTNews) - ImmunoGen, Inc. (IMGN) announced a clinical collaboration with Gilead Sciences, Inc. (GILD) to evaluate the safety and anti-leukemia activity of pivekimab sunirine in combination with magrolimab in patients with relapsed or refractory CD123-positive acute myeloid leukemia. The collaboration will be a new cohort in ImmunoGen's 802 study and will evaluate pivekimab in combination with magrolimab in up to 42 patients with R/R CD123-positive acute myeloid leukemia.

Magrolimab is a potential, first-in-class, investigational treatment designed to inhibit the CD47 protein.

For More Such Health News, visit rttnews.com.